A
653.83
1.40 (0.21%)
| Previous Close | 652.43 |
| Open | 647.90 |
| Volume | 413,741 |
| Avg. Volume (3M) | 395,266 |
| Market Cap | 40,014,331,904 |
| Price / Earnings (TTM) | 33.22 |
| Price / Earnings (Forward) | 48.78 |
| Price / Sales | 14.81 |
| Price / Book | 6.64 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
2.5
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bellevue Group Ag | 30 Jun 2025 | 571,039 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,070.00 (Guggenheim, 63.65%) | Buy |
| Median | 770.00 (17.77%) | |
| Low | 715.00 (Wedbush, 9.36%) | Buy |
| Average | 818.50 (25.19%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 658.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 04 Aug 2025 | 830.00 (26.94%) | Buy | 690.32 |
| Guggenheim | 01 Aug 2025 | 1,070.00 (63.65%) | Buy | 673.80 |
| HC Wainwright & Co. | 01 Aug 2025 | 774.00 (18.38%) | Buy | 673.80 |
| 01 Jul 2025 | 720.00 (10.12%) | Buy | 542.47 | |
| Morgan Stanley | 01 Aug 2025 | 766.00 (17.16%) | Buy | 673.80 |
| Wells Fargo | 31 Jul 2025 | 756.00 (15.63%) | Buy | 670.33 |
| Wedbush | 24 Jun 2025 | 715.00 (9.36%) | Buy | 568.06 |
| 11 Jun 2025 | 715.00 (9.36%) | Buy | 574.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Aug 2025 | Announcement | argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis |
| 31 Jul 2025 | Announcement | argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update |
| 24 Jul 2025 | Announcement | argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 |
| 30 Jun 2025 | Announcement | argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes |
| 20 Jun 2025 | Announcement | argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy |
| 10 Jun 2025 | Announcement | argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease |
| 03 Jun 2025 | Announcement | argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference |
| 28 May 2025 | Announcement | argenx Announces Results of Annual General Meeting of Shareholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |